miR-143 could increase the drug-sensitivity of prostate cancer by suppressing the expression of target protein KRAS, while the overexpression of miR-143 could also participate the regulation of EGFR/RAS/MAPK pathway and improve the sensitivity of prostate cancer cells to docetaxel. Here, KRAS is linked to prostate carcinoma.